5. Nektar Therapeutics ( NKTR) is a clinical-stage biopharmaceutical major. The company reported a loss of 24 cents per share for 2010 fourth quarter against a loss of 8 cents and 9 cents per share in the year-ago and quarter-ago periods, respectively. Loss per share is pegged at $1.31 for 2011 and $1.16 cents for 2012. The stock has a 73% upside over the next 12 months with a consensus target price of $15.4, analysts polled by Bloomberg forecast. In comparison, pharma giants Johnson & Johnson ( JNJ), Pfizer ( PFE), Merck ( MRK), Abbott Laboratories ( ABT), Bristol Myers Squibb ( BMY) and Eli Lilly ( LLY) have upsides of 1%-16%. Of the 11 analysts covering the stock, 8 recommend buying and 3 suggest holding, representing 73% buy ratings.